NR4A1 and cancer: Among those with CVD history, a minority of women had anthracyclines in the neo-adjuvant setting (n = 285, 13%); these tended to be younger, pre-menopausal, of higher socio-economic status, diagnosed with hormone-receptor positive cancers and at more advanced disease, compared to women with CVD that had anthracyclines in the adjuvant setting only (Supplementary Table 9).